Could a common HIV drug help fight resistant cancers?
NCT ID NCT06494579
First seen Jan 09, 2026 · Last updated May 07, 2026 · Updated 15 times
Summary
This early-phase study tests whether adding lamivudine, an HIV medication, can help control advanced solid tumors that no longer respond to standard immunotherapy. About 12 adults with various solid cancers will receive lamivudine alongside their current immunotherapy. The goal is to see if the combination is safe and can shrink tumors or slow their growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.